Thermo Fisher Beats Estimates on Biopharma Growth

The company reported first-quarter revenue of $11.01 billion and earnings of $5.44 per share. Growth in laboratory products offset weak diagnostic sales.

Xurve View
Insights:

THERMO FISHER SCIENTIFIC INC exceeded Wall Street expectations for both profit and revenue in the first quarter, driven by robust performance in its laboratory products and biopharma services division. Despite the positive financial results, shares of the United States-based company dropped 3.1% in premarket trading as investors weighed broader industry challenges.

The Thermo Fisher Scientific corporate signage is displayed at their facility in Waltham, Massachusetts, photographed on August 2, 2023. REUTERS/Brian Snyder/File Photo